Last updated: February 20, 2026
What is NDC 29033-0030?
The National Drug Code (NDC) 29033-0030 corresponds to Rifampin (Rifampicin), a broad-spectrum antibiotic used primarily for tuberculosis (TB) treatment, and in some cases for other bacterial infections. It is a generic formulation supplied by multiple manufacturers.
Market Overview
Market Size and Usage
Rifampin is a cornerstone in TB therapy, often prescribed in combination regimens. Its global market valuation is estimated at approximately USD 500 million in 2022, with a compound annual growth rate (CAGR) around 4% projected through 2027[1].
Key Market Segments
- Tuberculosis Treatment: 70% of rifampin sales. Primarily in high TB burden regions like Southeast Asia, Africa, and Eastern Europe.
- Other Bacterial Infections: 20%. Off-label uses include leprosy and certain meningitis cases.
- Research and Development: Approximately 10%, related to novel formulations or combination therapies.
Major Geographies
- United States: Mature market with stable demand, primarily in TB clinics.
- Emerging Markets: Rapid growth due to high TB prevalence.
- European Union: Controlled demand, with a focus on resistant TB strains.
Competitive Landscape
Multiple suppliers produce generic rifampin, including Mylan, Sandoz, and Teva. Patent expiration occurred in the late 1990s, resulting in significant price erosion and high competition.
Pricing Analysis
Current Price Points
- Average Wholesale Price (AWP): USD 0.75 per 150 mg capsule in the U.S.
- Average Sales Price (ASP): USD 0.60 per capsule.
Prices vary by quantity, formulation, and region. Bulk institutional contracts can reduce prices further, often below USD 0.50 per capsule.
Cost of Goods Sold (COGS)
Manufacturing costs range from USD 0.10 to USD 0.15 per capsule, including raw materials, packaging, and distribution.
Pricing Trends (2022-2027)
| Year |
Estimated Price per Capsule |
Change from Previous Year |
| 2022 |
USD 0.60 |
— |
| 2023 |
USD 0.58 |
-3.3% |
| 2024 |
USD 0.55 |
-5.2% |
| 2025 |
USD 0.53 |
-3.6% |
| 2026 |
USD 0.52 |
-1.9% |
| 2027 |
USD 0.50 |
-3.8% |
Slight declining trend correlates with increased generic competition, manufacturing efficiencies, and price pressure from procurement agencies.
Price Drivers
- Patent expiration: Simplifies market entry, driving prices down.
- Demand shifts: A focus on drug-resistant TB often switches demand to newer, combination therapies.
- Regulatory policies: Countries adopting price control measures directly impact medication pricing.
Future Price Projections
Factors Influencing Price
- Patent status: No patents in place, fostering strong generic competition.
- Regulatory environment: Price controls in emerging markets could constrain prices further.
- Market penetration: Growing TB treatment programs in Africa and Asia expand demand without significantly increasing prices.
- New formulations: Development of fixed-dose combinations (FDCs) could impact standalone rifampin prices, either increasing or decreasing overall market value.
2028-2032 Outlook
- Price per capsule likely stabilizes around USD 0.50–0.55.
- Price reductions of 1–2% annually remain plausible in mature markets.
- Opportunities for premium formulations in niche markets, such as controlled-release or combination therapies, could sustain higher prices in specific segments.
Summary of Market Drivers and Risks
| Drivers |
Risks |
| High TB prevalence in key emerging markets |
Price controls and procurement policies |
| Expiration of patents leading to increased generics |
Emergence of resistant strains reducing demand for traditional rifampin |
| Global focus on TB elimination |
Competition from new drugs and combination therapies |
Key Takeaways
- The global rifampin market, driven by TB treatment needs, remains sizable, with a valuation near USD 500 million in 2022.
- Prices per capsule are declining, averaging USD 0.60 in 2022, with a projected decrease toward USD 0.50–0.55 by 2032.
- Generics dominate pricing dynamics, with multiple manufacturers competing primarily on price.
- Regional price control measures and treatment protocols influence variability.
FAQs
1. How does patent expiration affect rifampin prices?
Patent expiry allowed multiple manufacturers to enter the market, increasing competition. Prices dropped significantly post-1990s.
2. What is the typical annual price reduction for rifampin?
Approximately 2-4% per year, based on current trends and competition dynamics.
3. Are there premium formulations expected to impact the market?
Yes, fixed-dose combinations and controlled-release versions may command higher prices in specific markets, though they constitute a small segment currently.
4. What regional factors influence rifampin pricing?
Price controls, procurement policies, and TB prevalence rates significantly impact regional variations.
5. How does resistance impact future markets?
Increasing drug-resistant TB strains may necessitate new drug regimens, potentially reducing demand for traditional rifampin or increasing reliance on newer formulations.
References
[1] MarketResearch.com. (2023). Global Tuberculosis Drugs Market Analysis. Retrieved from https://www.marketresearch.com
